Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28527648 | 0.95 | CYP3A4 (0.32) | CYP3A4 | |
| SCHEMBL28525796 | 0.95 | CYP3A4 (0.32) | CYP3A4 | |
| SCHEMBL80872 | 0.85 | — | — | |
| SCHEMBL702496 | 0.83 | TSHR (0.37) | — | |
| SCHEMBL16538439 | 0.81 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL2123586 | 0.80 | — | — | |
| SCHEMBL5473755 | 0.79 | — | — | |
| SCHEMBL5469923 | 0.79 | — | — | |
| SCHEMBL79248 | 0.79 | — | — | |
| SCHEMBL337263 | 0.78 | CYP3A4 (0.32) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095034-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-8129384-B2 | Imidazo[1,2-a]pyrazines as orexin receptor antagonists | GLAXO GROUP LIMITED (GB) | 2012-03-06 | — | — | US | disclosed |
| US-8093255-B2 | Imidazo[1,2-A]pyrimidines as orexin receptor antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20110288098-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2011-11-24 | — | — | US | disclosed |
| EP-2379550-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | Glaxo Group Limited (GB) | 2011-10-26 | — | — | EP | disclosed |
| US-20110257198-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2011-10-20 | — | — | US | disclosed |
| EP-2358713-A1 | IMIDAZOPYRIDAZINE DERIVATIVES ACTING AS OREXIN ANTAGONISTS | Glaxo Group Limited (GB) | 2011-08-24 | — | — | EP | disclosed |
| EP-2358712-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2011-08-24 | — | — | EP | disclosed |
| EP-2358711-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2011-08-24 | — | — | EP | disclosed |
| US-20100160345-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095034-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, GPR119 | CYP3A4 1947/4885 |
| US-20110288098-A1 | NOVEL COMPOUNDS | BRD4, HDAC6, ITPR3 | CYP3A4 310/4885 |
| US-20110257198-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, VIPR2 | CYP3A4 3797/4885 |
| US-20100160345-A1 | NOVEL COMPOUNDS | BRD4, HDAC6, ITPR3 | CYP3A4 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.